In this issue:
Obinutuzumab plus venetoclax or chlorambucil in previously untreated CLL
Sorafenib maintenance after alloHSCT in AML with FLT3 mutation
Q-TWiST analysis of glasdegib plus low-dose cytarabine for AML
PET–directed therapy for limited-stage DLBCL
Bendamustine/rituximab with bortezomib induction or lenalidomide continuation in FL
MRD after consolidation predicts outcomes in APL treated with ATRA + chemo
Outcomes of COVID-19 in patients with CLL
Involved field radiotherapy post HSCT in R/R lymphoma
Real-world study of first-line therapy in elderly DLBCL
HIV-associated NHL treated with EPOCH and vorinostat
Please login below to download this issue (PDF)